Viracta Therapeutics (VIRX)
(Delayed Data from NSDQ)
$0.84 USD
+0.02 (2.43%)
Updated May 2, 2024 03:59 PM ET
After-Market: $0.84 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VIRX 0.84 +0.02(2.43%)
Will VIRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VIRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIRX
Has IMARA (IMRA) Outpaced Other Medical Stocks This Year?
Does Sunesis (VIRX) Have the Potential to Rally 335% as Wall Street Analysts Expect?
VIRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma
Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year
Here's Why Assertio Holdings (ASRT) Stock is Up This Year
Other News for VIRX
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Day One wins FDA nod for brain cancer therapy, Ojemda
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Promising Clinical Trial Results Reinforce Buy Rating for Viracta Therapeutics